These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38264230)

  • 1. Correction: Trends in clinical characteristics and factors associated with initial prescription of SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus.
    Takahashi H; Suganuma Y; Ohno T; Nishimura R
    Diabetol Int; 2024 Jan; 15(1):141. PubMed ID: 38264230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in clinical characteristics and factors associated with initial prescription of SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus.
    Takahashi H; Suganuma Y; Ohno T; Nishimura R
    Diabetol Int; 2022 Oct; 13(4):606-614. PubMed ID: 36117921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction to: Metabolic surgery in treatment of obese Japanese patients with type 2 diabetes: a joint consensus statement from the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, and the Japan Society for the Study of Obesity.
    Sasaki A; Yokote K; Naitoh T; Fujikura J; Hayashi K; Hirota Y; Inagaki N; Ishigaki Y; Kasama K; Kikkawa E; Koyama H; Masuzaki H; Miyatsuka T; Nozaki T; Ogawa W; Ohta M; Okazumi S; Shimabukuro M; Shimomura I; Nishizawa H; Saiki A; Seki Y; Shojima N; Tsujino M; Ugi S; Watada H; Yamauchi T; Yamaguchi T; Ueki K; Kadowaki T; Tatsuno I;
    Diabetol Int; 2022 Jan; 13(1):31-32. PubMed ID: 35059239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction to: Metabolic surgery in treatment of obese Japanese patients with type 2 diabetes: a joint consensus statement from the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, and the Japan Society for the Study of Obesity.
    Sasaki A; Yokote K; Naitoh T; Fujikura J; Hayashi K; Hirota Y; Inagaki N; Ishigaki Y; Kasama K; Kikkawa E; Koyama H; Masuzaki H; Miyatsuka T; Nozaki T; Ogawa W; Ohta M; Okazumi S; Shimabukuro M; Shimomura I; Nishizawa H; Saiki A; Seki Y; Shojima N; Tsujino M; Ugi S; Watada H; Yamauchi T; Yamaguchi T; Ueki K; Kadowaki T; Tatsuno I;
    Diabetol Int; 2022 Jan; 13(1):33-34. PubMed ID: 35059240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction to: Japanese Clinical Practice Guideline for Diabetes 2016.
    Haneda M; Noda M; Origasa H; Noto H; Yabe D; Fujita Y; Goto A; Kondo T; Araki E
    Diabetol Int; 2019 Jan; 10(1):83. PubMed ID: 30800567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction to: Japanese Clinical Practice Guideline for Diabetes 2016.
    Haneda M; Noda M; Origasa H; Noto H; Yabe D; Fujita Y; Goto A; Kondo T; Araki E
    Diabetol Int; 2020 Apr; 11(2):163. PubMed ID: 32206488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.
    Ito H; Shinozaki M; Nishio S; Abe M
    Expert Opin Pharmacother; 2016 Oct; 17(15):2073-84. PubMed ID: 27592508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?-a cross sectional analysis of a nationwide Japanese claims database.
    Anan G; Kikuchi D; Omae K; Hirose T; Okada K; Mori T
    Endocr J; 2023 Nov; 70(11):1103-1107. PubMed ID: 37673640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. There is a Close Association Between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study.
    Kinoshita T; Shimoda M; Sanada J; Fushimi Y; Hirata Y; Irie S; Obata A; Kimura T; Hirukawa H; Kohara K; Tatsumi F; Kamei S; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Ther; 2018 Aug; 9(4):1569-1580. PubMed ID: 29931506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Type 1 Diabetes Mellitus on Body Composition and Glucose Variabilities: Single-Arm, Exploratory Trial.
    Baba Y; Ishibashi R; Takasaki A; Ito C; Watanabe A; Tokita M; Meguro M; Harama T; Hirayama K; Yamamoto T; Nakamura S; Koshizaka M; Maezawa Y; Uchida D; Okajima F
    Diabetes Ther; 2021 May; 12(5):1415-1427. PubMed ID: 33738773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study.
    Horii T; Oikawa Y; Kunisada N; Shimada A; Atsuda K
    BMJ Open Diabetes Res Care; 2020 Nov; 8(2):. PubMed ID: 33246930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction to: Non-autoimmune acute-onset type 1 diabetes mellitus newly developed in an elderly patient presenting elevation of serum pancreatic exocrine enzymes.
    Kanzaki A; Matsuda M; Yokota S; Takai K; Murai J; Otsuka A; Koyama H; Nakamura T
    Diabetol Int; 2022 Jan; 13(1):314. PubMed ID: 35073563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction: Patients with gestational diabetes mellitus may be treated in both early and late pregnancy, especially in patients with pre-pregnancy overweight: A cross-sectional study in Japan.
    Takemoto A; Nagai Y; Kawanabe S; Nakagawa T; Matsumoto K; Hasegawa J; Suzuki N; Tanaka Y; Sone M
    Diabetol Int; 2024 Apr; 15(2):313. PubMed ID: 38524934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus.
    Mukai J; Kanno S; Kubota R
    Sci Rep; 2021 Jun; 11(1):13472. PubMed ID: 34188120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction to: Impact of actual waiting time and perceived waiting time on treatment satisfaction in patients receiving outpatient diabetes care.
    Toga-Sato S; Tosaki T; Kondo M; Tsunekawa S; Kato Y; Nakamura J; Kamiya H
    Diabetol Int; 2021 Jul; 12(3):301-302. PubMed ID: 34157059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
    Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
    Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
    Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
    Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center.
    Sugiyama S; Jinnouchi H; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    J Clin Med Res; 2019 Apr; 11(4):267-274. PubMed ID: 30937117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Factors Associated with Initial Decrease in Body-Fat Percentage Induced by Add-on Sodium-Glucose Co-transporter 2 Inhibitors in Patient with Type 2 Diabetes Mellitus.
    Kurinami N; Sugiyama S; Nishimura H; Morita A; Yoshida A; Hieshima K; Miyamoto F; Kajiwara K; Jinnouchi K; Jinnouchi T; Jinnouchi H
    Clin Drug Investig; 2018 Jan; 38(1):19-27. PubMed ID: 29098566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.